Please login to the form below

Not currently logged in
Email:
Password:

chemotherapy

This page shows the latest chemotherapy news and features for those working in and with pharma, biotech and healthcare.

J&J’s targeted bladder cancer treatment gets US approval

J&J’s targeted bladder cancer treatment gets US approval

The drug, which will only be used in those whose disease has progressed during or following prior platinum-containing chemotherapy, received a breakthrough designation from the FDA in September last year,

Latest news

More from news
Approximately 6 fully matching, plus 776 partially matching documents found.

Latest Intelligence

  • Combining therapies and combining research Combining therapies and combining research

    Without effective antibiotics, much of the success of modern medicine, such as the levels of unprecedented survival rates from major surgery or super effective, chemotherapy treatment, would be totally compromised.

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    In December the FDA approved its use in combination with Avastin and chemotherapy in non-squamous NSCLC patients, based on results from the IMpower150 study. ... Keytruda monotherapy showed significant improvement in overall survival compared with

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    be treated with intensive chemotherapy. ... are ineligible for intensive chemotherapy, to go along with its existing indications in chronic lymphocytic leukaemia (CLL).

  • Is China ready for a pharmaceutical gold rush?

    Earlier this year, data showed Keytruda combined with chemotherapy could cut the risk of death among previously untreated lung cancer patients by 51%.

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    that has not spread widely around the body after platinum chemotherapy or radiotherapy. ... However, recent overall survival results from the MYSTIC trial, which studied Imfinzi with CTLA4 inhibitor tremelimumab, have just confirmed the combination

More from intelligence
Approximately 0 fully matching, plus 25 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics